Scleroderma Research Treatments Trials

Completed: Inconclusive or Difficult to Study

Bovine Collagen for Diffuse Scleroderma

Phase II was completed in April 2005.

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen (CI) treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Although the results from this trial did not meet the primary outcome goals, the findings from exploratory analyses indicated that CI treatment may benefit patients with late-phase dcSSc. This new treatment strategy and preliminary clinical observations in patients with dcSSc need to be corroborated. Postlethwaite AE. Arthritis Rheum. 2008 Jun;58(6):1810-22. (PubMed)

Oral Type 1 Collagen in Scleroderma. This is a 15-month study to find out if taking type I collagen by mouth will improve diffuse systemic sclerosis (scleroderma). We will randomly assign 168 patients to receive type I collagen from cows or a placebo (inactive treatment) for 12 months. Study dates 2000-2005. ClinicalTrials.gov. This was the original study.

DMSO (Dimethyl Sulfoxide) and MSM

No Current Studies; No Enrollment.

DMSO is an interesting treatment, which is difficult to study in double-blind trials. Read the latest DMSO Scleroderma studies and decide for yourself.

Scleredema and diabetic sclerodactyly. A 40-year-old man presented with hardening of the skin of his hands and upper back, which had slowly worsened with time. His medical history included insulin-dependent diabetes mellitus since childhood. This patient has improved with aminobenzoate, colchicine, and DMSO gel. Gruson LM. Dermatol Online J. 2005 Dec 30;11(4):3.

Also see: Interstitial Cystitis.

Also See

Sjögren's Treatments & Clinical Trials
Scleroderma Medical News
Scleroderma Symptoms (treatments are listed for each symptom)

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: